Provided by Tiger Trade Technology Pte. Ltd.

Protagonist Therapeutics

103.78
+0.11000.11%
Post-market: 103.780.00000.00%16:22 EDT
Volume:601.64K
Turnover:62.28M
Market Cap:6.62B
PE:-50.62
High:104.31
Open:101.59
Low:101.59
Close:103.67
52wk High:107.84
52wk Low:39.60
Shares:63.81M
Float Shares:43.15M
Volume Ratio:0.71
T/O Rate:1.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0500
EPS(LYR):-2.0500
ROE:-20.18%
ROA:-13.99%
PB:10.77
PE(LYR):-50.62

Loading ...

Protagonist Therapeutics Inc: Nda for Rusfertide Submitted to US FDA With Potential Approval & Launch This Year

THOMSON REUTERS
·
Feb 26

Protagonist Therapeutics: to Opt-Out of 50:50 Profit Sharing Arrangement for Rusfertide With Takeda During a 90-Day Window Expected to Open in Q2

THOMSON REUTERS
·
Feb 26

Protagonist Therapeutics posts FY 2025 license and collaboration revenue of USD 46.0 million down 89.4%

Reuters
·
Feb 26

Protagonist Therapeutics CEO Dinesh V. Patel to Speak at Multiple Investment Bank Conferences in March 2026

Reuters
·
Feb 24

Protagonist Therapeutics Inc expected to post a loss of 53 cents a share - Earnings Preview

Reuters
·
Feb 20

Protagonist Therapeutics Director Lewis T. Williams Disposes of Common Shares

Reuters
·
Feb 19

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.
·
Feb 09

Director’s Big Move: Major Insider Stock Sale Shakes Up Protagonist Therapeutics

TIPRANKS
·
Feb 07

Protagonist Therapeutics Director William D. Waddill Reports Sale of Common Shares

Reuters
·
Feb 07

Protagonist Therapeutics Is Maintained at Buy by Jefferies

Dow Jones
·
Feb 03

Protagonist Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 31

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Unicycive Therapeutics (UNCY)

TIPRANKS
·
Jan 30

Protagonist Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $117 From $80

THOMSON REUTERS
·
Jan 30

Arturo Molina, Chief Medical Officer, Reports Disposal of Protagonist Therapeutics Common Shares

Reuters
·
Jan 28

Have Insiders Sold Protagonist Therapeutics Shares Recently?

Simply Wall St.
·
Jan 23

Top Brass at Protagonist Therapeutics Quietly Cash In on Major Stock Moves

TIPRANKS
·
Jan 22

Protagonist Therapeutics CFO Asif Ali Reports Sale of Common Shares

Reuters
·
Jan 22

H.C. Wainwright Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

TIPRANKS
·
Jan 16

Protagonist Therapeutics (PTGX) Valuation Check After Strong Multi Year Return And Recent Share Price Pullback

Simply Wall St.
·
Jan 16

High Growth Tech Stocks In The US For January 2026

Simply Wall St.
·
Jan 09